Get started
Author

Susan M. Pederson

Efficacy and safety of eptinezumab in patients with chronic migraine
2020 · Richard B. Lipton, Peter J. Goadsby, et al. · Neurology · 400
PDF
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
2020 · Messoud Ashina, Joel Saper, et al. · Cephalalgia · 387
PDF
Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency
2006 · Amy E. Lovejoy, Tom C. Reynolds, et al. · Blood · 118
PDF
B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin
2010 · Stacey R Dillon, Brandon Harder, et al. · Arthritis Research & Therapy · 106
PDF
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
2020 · Stephen Silberstein, Merle Diamond, et al. · The Journal of Headache and Pain · 103
PDF
Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
2021 · David Kudrow, Roger K. Cady, et al. · BMC Neurology · 91
PDF
Population pharmacokinetic and exposure‐response analysis of eptinezumab in the treatment of episodic and chronic migraine
2020 · Brian Baker, Barbara Schaeffler, et al. · Pharmacology Research & Perspectives · 66
PDF
Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide
2019 · Cristina Moldovan Loomis, Benjamin Dutzar, et al. · Journal of Pharmacology and Experimental Therapeutics · 60
PDF
Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study
2020 · Timothy R. Smith, Marina Janelidze, et al. · Clinical Therapeutics · 56
Preclinical safety of recombinant human thrombin
2006 · Jane K. Heffernan, Rafael A. Ponce, et al. · Regulatory Toxicology and Pharmacology · 31
Preclinical Safety and Pharmacokinetics of Recombinant Human Factor XIII
2005 · Rafael A. Ponce, Jennifer E. Visich, et al. · Toxicologic Pathology · 22
Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum
2014 · Alexander Colbert, Amber Umble-Romero, et al. · mAbs · 21
Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs
2014 · Alex Colbert, Amber Umble-Romero, et al. · mAbs · 18
PDF
Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients
2021 · Brian Baker, Barbara Schaeffler, et al. · Endocrinology Diabetes & Metabolism · 13
PDF
Bioanalytical Challenges and Unique Considerations to Support Pharmacokinetic Characterization of Bispecific Biotherapeutics
2019 · Mark Ma, Kelly Colletti, et al. · Bioanalysis · 10
Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine
2021 · Susan Pederson, David M. Biondi, et al. · Frontiers in Immunology · 8
Pharmacokinetics and Pharmacodynamics of Pegylated Interferon Lambda-1 in Cynomolgus Monkeys
2012 · Kelly A. Byrnes-Blake, Susan Pederson, et al. · Journal of Interferon & Cytokine Research · 8
Corrigendum to “Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study” [Clin Therapeut 42 (12) (2020) 2254–2265]
2021 · Timothy R. Smith, Marina Janelidze, et al. · Clinical Therapeutics · 5
PDF
Differences in Exposure Between Intravenously (IV) Administered Eptinezumab and Subcutaneously (SC) Administered CGRP Inhibitor Monoclonal Antibodies After Single Therapeutic Doses (708)
2020 · Brian Baker, Martin Beliveau, et al. · Neurology · 3
Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody for the Preventive Treatment of Migraine (1790)
2021 · Susan M. Pederson, David Biondi, et al. · Neurology
Recombinant Thrombin Has a Superior Immunogenicity Profile Compared with Bovine Thrombin in a Well-Controlled, Randomized, Double-Blind, Phase 3 Study of Topically Applied Thrombins in Four Surgical Settings.
2007 · Linda A. Zuckerman, Susan Pederson, et al. · Blood
Works count: 30
Citation count: 1,526
H-index: 13
I10-index: 15
Year
Topic
Type